230 related articles for article (PubMed ID: 27557550)
1. Regional Differences in Serotonin Transporter Occupancy by Escitalopram: An [
Kim E; Howes OD; Kim BH; Chon MW; Seo S; Turkheimer FE; Lee JS; Lee YS; Kwon JS
Clin Pharmacokinet; 2017 Apr; 56(4):371-381. PubMed ID: 27557550
[TBL] [Abstract][Full Text] [Related]
2. Time-course of serotonin transporter occupancy by single dose of three SSRIs in human brain: A positron emission tomography study with [(11)C]DASB.
Arakawa R; Tateno A; Kim W; Sakayori T; Ogawa K; Okubo Y
Psychiatry Res Neuroimaging; 2016 May; 251():1-6. PubMed ID: 27082864
[TBL] [Abstract][Full Text] [Related]
3. In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram.
Klein N; Sacher J; Geiss-Granadia T; Attarbaschi T; Mossaheb N; Lanzenberger R; Pötzi C; Holik A; Spindelegger C; Asenbaum S; Dudczak R; Tauscher J; Kasper S
Psychopharmacology (Berl); 2006 Oct; 188(3):263-72. PubMed ID: 16955282
[TBL] [Abstract][Full Text] [Related]
4. Higher serotonin transporter availability in early-onset obsessive-compulsive disorder patients undergoing escitalopram treatment: A [
Lee J; Kim BH; Kim E; Howes OD; Cho KIK; Yoon YB; Kwon JS
Hum Psychopharmacol; 2018 Jan; 33(1):. PubMed ID: 29210107
[TBL] [Abstract][Full Text] [Related]
5. Altered serotonin transporter binding potential in patients with obsessive-compulsive disorder under escitalopram treatment: [11C]DASB PET study.
Kim E; Howes OD; Park JW; Kim SN; Shin SA; Kim BH; Turkheimer FE; Lee YS; Kwon JS
Psychol Med; 2016 Jan; 46(2):357-66. PubMed ID: 26423910
[TBL] [Abstract][Full Text] [Related]
6. Serotonin transporter occupancy by escitalopram and citalopram in the non-human primate brain: a [(11)C]MADAM PET study.
Finnema SJ; Halldin C; Bang-Andersen B; Bundgaard C; Farde L
Psychopharmacology (Berl); 2015 Nov; 232(21-22):4159-67. PubMed ID: 25980484
[TBL] [Abstract][Full Text] [Related]
7. Prediction of SSRI treatment response in major depression based on serotonin transporter interplay between median raphe nucleus and projection areas.
Lanzenberger R; Kranz GS; Haeusler D; Akimova E; Savli M; Hahn A; Mitterhauser M; Spindelegger C; Philippe C; Fink M; Wadsak W; Karanikas G; Kasper S
Neuroimage; 2012 Nov; 63(2):874-81. PubMed ID: 22828162
[TBL] [Abstract][Full Text] [Related]
8. Regional differences in SERT occupancy after acute and prolonged SSRI intake investigated by brain PET.
Baldinger P; Kranz GS; Haeusler D; Savli M; Spies M; Philippe C; Hahn A; Höflich A; Wadsak W; Mitterhauser M; Lanzenberger R; Kasper S
Neuroimage; 2014 Mar; 88():252-62. PubMed ID: 24121201
[TBL] [Abstract][Full Text] [Related]
9. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study.
Meyer JH; Wilson AA; Sagrati S; Hussey D; Carella A; Potter WZ; Ginovart N; Spencer EP; Cheok A; Houle S
Am J Psychiatry; 2004 May; 161(5):826-35. PubMed ID: 15121647
[TBL] [Abstract][Full Text] [Related]
10. Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [123I]ADAM SPECT study.
Klein N; Sacher J; Geiss-Granadia T; Mossaheb N; Attarbaschi T; Lanzenberger R; Spindelegger C; Holik A; Asenbaum S; Dudczak R; Tauscher J; Kasper S
Psychopharmacology (Berl); 2007 Apr; 191(2):333-9. PubMed ID: 17235610
[TBL] [Abstract][Full Text] [Related]
11. [Escitalopram: a selective inhibitor and allosteric modulator of the serotonin transporter].
Mnie-Filali O; El Mansari M; Scarna H; Zimmer L; Sánchez C; Haddjeri N
Encephale; 2007 Dec; 33(6):965-72. PubMed ID: 18789789
[TBL] [Abstract][Full Text] [Related]
12. [11C]-DASB, a tool for in vivo measurement of SSRI-induced occupancy of the serotonin transporter: PET characterization and evaluation in cats.
Ginovart N; Wilson AA; Meyer JH; Hussey D; Houle S
Synapse; 2003 Feb; 47(2):123-33. PubMed ID: 12454950
[TBL] [Abstract][Full Text] [Related]
13. Brain serotonin transporter occupancy by oral sibutramine dosed to steady state: a PET study using (11)C-DASB in healthy humans.
Talbot PS; Bradley S; Clarke CP; Babalola KO; Philipp AW; Brown G; McMahon AW; Matthews JC
Neuropsychopharmacology; 2010 Feb; 35(3):741-51. PubMed ID: 19890256
[TBL] [Abstract][Full Text] [Related]
14. The interaction of escitalopram and R-citalopram at the human serotonin transporter investigated in the mouse.
Jacobsen JP; Plenge P; Sachs BD; Pehrson AL; Cajina M; Du Y; Roberts W; Rudder ML; Dalvi P; Robinson TJ; O'Neill SP; Khoo KS; Morillo CS; Zhang X; Caron MG
Psychopharmacology (Berl); 2014 Dec; 231(23):4527-40. PubMed ID: 24810106
[TBL] [Abstract][Full Text] [Related]
15. Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomography.
Comley RA; Salinas CA; Slifstein M; Petrone M; Marzano C; Bennacef I; Shotbolt P; Van der Aart J; Neve M; Iavarone L; Gomeni R; Laruelle M; Gray FA; Gunn RN; Rabiner EA
J Pharmacol Exp Ther; 2013 Aug; 346(2):311-7. PubMed ID: 23685546
[TBL] [Abstract][Full Text] [Related]
16. Serotonin transporter occupancy and the functional neuroanatomic effects of citalopram in geriatric depression.
Smith GS; Kahn A; Sacher J; Rusjan P; van Eimeren T; Flint A; Wilson AA
Am J Geriatr Psychiatry; 2011 Dec; 19(12):1016-25. PubMed ID: 21841458
[TBL] [Abstract][Full Text] [Related]
17. 5-HTT and 5-HT(1A) receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects.
Stenkrona P; Halldin C; Lundberg J
Eur Neuropsychopharmacol; 2013 Oct; 23(10):1190-8. PubMed ID: 23428337
[TBL] [Abstract][Full Text] [Related]
18. An open-label positron emission tomography study to evaluate serotonin transporter occupancy following escalating dosing regimens of (R)-(-)-O-desmethylvenlafaxine and racemic O-desmethylvenlafaxine.
Frankle WG; Robertson B; Maier G; Paris J; Asmonga D; May M; Himes ML; Mason NS; Mathis CA; Narendran R
Synapse; 2018 Mar; 72(3):. PubMed ID: 29216407
[TBL] [Abstract][Full Text] [Related]
19. PET measurement of serotonin transporter occupancy: a comparison of escitalopram and citalopram.
Lundberg J; Christophersen JS; Petersen KB; Loft H; Halldin C; Farde L
Int J Neuropsychopharmacol; 2007 Dec; 10(6):777-85. PubMed ID: 17201996
[TBL] [Abstract][Full Text] [Related]
20. Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in-vitro and in-vivo studies.
Mansari ME; Wiborg O; Mnie-Filali O; Benturquia N; Sánchez C; Haddjeri N
Int J Neuropsychopharmacol; 2007 Feb; 10(1):31-40. PubMed ID: 16448580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
